3-(piperidin-4-yl)-1H-indole-5-carbonitrile | 173150-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(piperidin-4-yl)-1H-indole-5-carbonitrile
• 英文别名: 5-cyano-3-(piperidin-4-yl)-1H-indole；3-(4-piperidinyl)-5-cyanoindole；3-piperidin-4-yl-1H-indole-5-carbonitrile
• CAS: 173150-57-7
• 化学式: C₁₄H₁₅N₃
• mdl: MFCD26741993
• 分子量: 225.293
• InChiKey: FKYYQTPGCWRMGM-UHFFFAOYSA-N

物化性质

• 沸点：
  460.9±45.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  51.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-苯氧基溴丙烷 、 3-(piperidin-4-yl)-1H-indole-5-carbonitrile 在 三乙胺 作用下， 以 甲醇 为溶剂， 以44%的产率得到3-[1-(3-phenoxypropyl)-4-piperidinyl]-5-cyanoindole
  参考文献：
  名称：

  Antipsychotic heterocycle compounds

  摘要：

  式I的化合物是有用的抗精神病和抗抑郁药物，表现出对5-HT再摄取和多巴胺D2受体的强效抑制作用。Ar—Y—(CH2)m—Z 在式I中：Ar从1中选择Z为II或III；2Y为硫或氧；R1和R4分别选择自H和较低的烷基；R2、R3、R6和R7分别选择自H、卤素和较低的烷氧基；R5从H、卤素、较低的烷氧基和氰基中选择；m为2-6之间的整数；n为零或整数1或2；虚线代表可选的双键。

  公开号：

  US20020072611A1
• 作为产物：
  描述：

  5-氰基吲哚 在 盐酸 、 5%-palladium/activated carbon 、 甲酸铵 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 反应 21.0h， 生成 3-(piperidin-4-yl)-1H-indole-5-carbonitrile
  参考文献：
  名称：

  Benzimidazoles: Novel Mycobacterial Gyrase Inhibitors from Scaffold Morphing

  摘要：

  Type II topoisomerases are well conserved across the bacterial species, and inhibition of DNA gyrase by fluoroquinolones has provided an attractive option for treatment of tuberculosis (TB). However, the emergence of fluoroquinolone-resistant strains of Mycobacterium tuberculosis (Mtb) poses a threat for its sustainability. A scaffold hopping approach using the binding mode of novel bacterial topoisomerase inhibitors (NBTIs) led to the identification of a novel class of benzimidazoles as DNA gyrase inhibitors with potent anti-TB activity. Docking of benzimidazoles to a NBTI bound crystal structure suggested that this class of compound makes key contacts in the enzyme active site similar to the reported NBTIs. This observation was further confirmed through the measurement of DNA gyrase inhibition, and activity against Mtb strains harboring mutations that confer resistance to aminopiperidines based NBTIs and Mtb strains resistant to moxifloxacin. Structure activity relationship modification at the C-7 position of the left-hand side ring provided further avenue to improve hERG selectivity for this chemical series that has been the major challenges for NBTIs.

  DOI：

  10.1021/ml5001728

文献信息

• 5-HT Reuptake Inhibitors with 5-HT_1B/1D Antagonistic Activity:  A New Approach toward Efficient Antidepressants
  作者：Lisa Matzen、Christoph van Amsterdam、Wilfried Rautenberg、Hartmut E. Greiner、Jürgen Harting、Christoph A. Seyfried、Henning Böttcher

  DOI：10.1021/jm9811054

  日期：2000.3.1

  block the sumatriptan-induced inhibition of potassium-evoked [(3)H]5-HT release. The 5-HT reuptake inhibition of the ureas determined in rat brain synaptosomes was found to be either increased or decreased as compared to the uncoupled indole derivatives indicating that the reuptake inhibition shown by the ureas is not only due to the indole part but also affected by the aniline moiety of the molecule. Among

  作为我们针对新型潜在抗抑郁药的研究计划的一部分，已制备了一系列不对称尿素，并将其评估为具有5-HT（1B / 1D）拮抗活性的5-HT再摄取抑制剂。这些化合物的设计基于各种吲哚衍生物（以前显示出抑制5-HT再摄取的作用）与三个不同的苯胺部分的偶联，而苯胺部分是已知的5-HT（1B / 1D）配体的一部分。分别在大鼠额叶皮层中使用[（125）I]碘氰基吲哚醇，在小腿纹状体中使用[（3）H] 5-HT以及在大鼠海马中使用[（3）H] 8-OH-DPAT作为放射性配体的结合实验，揭示了与5-HT（1A）和5-HT（1D）受体对许多化合物的亲和力相比，对5-HT（1B）受体的亲和力明显更高，其中4-（5-氟-1H-吲哚-3-基）哌啶-1-甲酸[4-甲氧基-3-（4-甲基哌嗪-1-基）苯基]酰胺（5），相应的4-氟-1H-吲哚-3-基类似物21a和相应的6-氟-1H-吲哚-3-基类似物21b。苯胺部
• [EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
  申请人：ASTRAZENECA AB

  公开号：WO2009081197A1

  公开（公告）日：2009-07-02

  The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  该发明涉及式(I)的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所示。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在制备用于预防或治疗雄激素受体相关疾病的药物中的应用。
• Inhibition of serotonin reuptake
  申请人：Eli Lilly and Company

  公开号：US05846982A1

  公开（公告）日：1998-12-08

  This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.

  这项发明提供了一种用于抑制哺乳动物中5-羟色胺再摄取的化合物和方法。
• 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake
  申请人：ELI LILLY AND COMPANY

  公开号：EP0812826A1

  公开（公告）日：1997-12-17

  The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1 is H, halo, formyl, C1-C4 alkyl, C1-C4 alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2 is H or halo; R3 is H, C1-C4 alkyl, (C1-C4 alkylene)-aryl, or -CH2-Y-NR7R8; R4 is H, C1-C4 alkyl, C1-C5 acyl, or phenylsulfonyl; R5 is H or OH; R6 is H or methyl; Y is -CH2- or -C(O)-; R7 is pyridinyl; and R8 is H or -C(O)-(C3-C6 cycloalkyl); and pharmaceutically acceptable salts thereof.

  化合物的药用途：其中Z是formulaA-B结构，-C=CH-或-C(R5)-CH2-；X是S或NR4；R1是H、卤素、甲酰基、C1-C4烷基、C1-C4烷氧基、噻吩甲氧基、4,5-二氢噻唑-2-基、氰基、硝基、羧酰胺基、三氟甲基或羟基；R2是H或卤素；R3是H、C1-C4烷基、(C1-C4烷基)-芳基，或-CH2-Y-NR7R8；R4是H、C1-C4烷基、C1-C5酰基，或苯基磺酰基；R5是H或OH；R6是H或甲基；Y是-CH2-或-C(O)-；R7是吡啶基；R8是H或-C(O)-(C3-C6环烷基)；以及其药用上可接受的盐。
• BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155
  申请人：Bradbury Robert Hugh

  公开号：US20100016279A1

  公开（公告）日：2010-01-21

  The invention concerns bicyclic compounds of Formula I wherein the integers X 1 , X 2 , X 3 , Ring A, R 4 , R 5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  本发明涉及公式I的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m如描述中所定义。本发明还涉及制备这种化合物的方法、包含它们的制药组合物以及它们在制造用于预防或治疗与雄激素受体相关疾病的药物中的应用。